Avanafil for erectile dysfunction.

Area of Science:

• Pharmacology and Therapeutics
• Urology

Background:

• Erectile dysfunction (ED) is a common condition affecting men's sexual health.
• Phosphodiesterase type 5 (PDE5) inhibitors are a primary treatment for ED.

Purpose of the Study:

• To review the pharmacology, pharmacokinetics, safety, and efficacy of avanafil.
• To evaluate clinical trial data for avanafil in treating ED.

Main Methods:

• Searched MEDLINE, International Pharmaceutical Abstracts, ClinicalTrials.gov, and Google Scholar (1966-July 2013).
• Included English-language articles on avanafil for ED in human subjects.
• Identified five clinical trials and reviewed their references.

Main Results:

• Avanafil is a selective PDE5 inhibitor with rapid oral absorption (Tmax 30-45 min) and a 5-hour half-life.
• Effective in improving erectile function scores; safety profile comparable to other PDE5 inhibitors.
• Common adverse effects include headache, flushing, and nasal congestion; no dosage adjustments needed for renal/hepatic function, age, or gender.

Conclusions:

• Avanafil is a potent PDE5 inhibitor.
• Demonstrates efficacy as a treatment option for erectile dysfunction.